On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
ThursdayJun 15, 2017 4:00 pm

Stellar Biotechnologies, Inc. (NASDAQ: SBOT) Starts Presentation at the 2017 Marcum Microcap Conference

Stellar Biotechnologies (NASDAQ: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. For more information, visit the company's website at stellarbiotechnologies.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press…

Continue Reading

ThursdayJun 15, 2017 4:00 pm

GWG Holdings, Inc. (NASDAQ: GWGH) Starts Presentation at the 2017 Marcum Microcap Conference

GWG Holdings (NASDAQ: GWGH) the parent company of GWG Life, is a financial services company committed to transforming the life insurance industry through disruptive and innovative products and services. Already a recognized disruptor in the life insurance secondary market, GWG Life seeks to further transform the industry by continuing to create innovative products and services. As of March 31, 2017, GWG Life's growing portfolio consisted of over $1.4 billion in face value of policy benefits. Since 2006, GWG Life has purchased over $2.4 billion in life insurance policy benefits and paid seniors more than $418.4 million for their life insurance.…

Continue Reading

ThursdayJun 15, 2017 4:00 pm

PwrCor, Inc. (PWCO) Starts Presentation at the 2017 Marcum Microcap Conference

PwrCor (OTC: PWCO) is a clean energy technology company launching advanced solutions for the waste heat to energy, geothermal, and solar thermal markets. PwrCorTM engines use proprietary technology that can cost effectively convert ultra-low-grade heat to usable mechanical or electrical energy.  PwrCorTM uses no fossil fuels, does not operate via combustion, has no emissions, and does not process any working fluids that are flammable, harmful to the environment, or costly to replace.  PwrCorTM is scalable, modular, and runs relatively silently, all within a small footprint. For more information, visit the company's website at www.pwrcor.com About NetworkNewsWire NetworkNewsWire (NNW) is an…

Continue Reading

ThursdayJun 15, 2017 4:00 pm

Nephros, Inc. (NEPH) Starts Presentation at the 2017 Marcum Microcap Conference

Nephros (OTC: NEPH) is a commercial-stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria, virus and endotoxin from water used by patients. For more information, visit the company's website at www.nephros.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that…

Continue Reading

ThursdayJun 15, 2017 4:00 pm

Rxi Pharmaceuticals Corp. (NASDAQ: RXII) Starts Presentation at the 2017 Marcum Microcap Conference

Rxi Pharmaceuticals (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs. RXi scientists have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and it actively pursues research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies.   For more information, visit the company's website at www.rxipharma.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that…

Continue Reading

ThursdayJun 15, 2017 3:35 pm

PV Nano Cell (PVNNF) Increases IP War Chest as Japanese Patent Office Grants Silver Nano Particles Patent for 3D Printing

A recent Forbes (http://nnw.fm/4dz6G) article shows just how far Additive Manufacturing (AM), a.k.a. 3D Printing, has come, reporting that the government of Dubai, United Arab Emirates, ‘has set a target for 25 percent of buildings to be 3D-printed by 2030.’ Apparently, the AM industry now believes it has the technology to “print” houses. That technological prowess also appears to extend to smaller objects, much smaller, where the challenges are different but just as formidable. An Economist feature (http://nnw.fm/0D9oB) tells how a Chinese contract manufacturer is using 3D printers ‘to print electronic circuits, such as antennae and sensors, directly into products…

Continue Reading

ThursdayJun 15, 2017 3:30 pm

Neurotrope, Inc. (NASDAQ: NTRP) Starts Presentation at the 2017 Marcum Microcap Conference

Neurotrope (NASDAQ: NTRP) is developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The scientific basis of the treatment is activation of Protein Kinase C isozymes ε and α by Bryostatin-1, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's dementia. For more information, visit the…

Continue Reading

ThursdayJun 15, 2017 3:30 pm

Jaguar Animal Health, Inc. (NASDAQ: JAGX) Starts Presentation at the 2017 Marcum Microcap Conference

Jaguar Animal Health (NASDAQ: JAGX) is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA. For more information, visit the company's website at jaguaranimalhealth.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access…

Continue Reading

ThursdayJun 15, 2017 3:30 pm

Kush Bottles, Inc. (KSHB) Starts Presentation at the 2017 Marcum Microcap Conference

Kush Bottles (OTC: KSHB) is a dynamic sales platform that provides unique products and services for both businesses and consumers in the cannabis industry. Founded in 2010 as a packaging and supplies company for dispensaries and growers, Kush Bottles has sold more than 100 million units and now regularly services more than 4,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. The company has facilities in the three largest U.S. cannabis markets and a local sales presence in every major U.S. cannabis market. For more information, visit the company's website at www.kushbottles.com…

Continue Reading

ThursdayJun 15, 2017 3:30 pm

BioCorRx, Inc. (BICX) Starts Presentation at the 2017 Marcum Microcap Conference

BioCorRx (OTC: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment program, consists of two main components. First is an outpatient implant procedure that delivers naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second is a proprietary counseling program tailored for treatment of alcoholism and substance abuse addictions and long-term naltrexone treatment. The company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is developing a new injectable naltrexone technology. For more information, visit the company’s website at…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217